{"id":48076,"date":"2022-09-07T20:01:49","date_gmt":"2022-09-07T18:01:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-lenalidomide-capsules-in-the-u-s-with-two-of-six-strengths-eligible-for-first-to-market-180-day-exclusivity\/"},"modified":"2022-09-07T20:01:49","modified_gmt":"2022-09-07T18:01:49","slug":"dr-reddys-laboratories-announces-the-launch-of-lenalidomide-capsules-in-the-u-s-with-two-of-six-strengths-eligible-for-first-to-market-180-day-exclusivity","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dr-reddys-laboratories-announces-the-launch-of-lenalidomide-capsules-in-the-u-s-with-two-of-six-strengths-eligible-for-first-to-market-180-day-exclusivity\/","title":{"rendered":"Dr. Reddy’s Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity"},"content":{"rendered":"
\n

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–$RDY<\/a> #Affordablemedicines<\/a>–Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s\u201d) today announced the launch, in the U.S. market, of Lenalidomide Capsules, a therapeutic equivalent generic version of REVLIMID\u00ae (lenalidomide) Capsules approved by U.S. Food and Drug Administration (USFDA). With this volume-limited launch, Dr. Reddy\u2019s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity,\u201d says Marc Kikuchi, CEO, North America Generics, Dr. Reddy\u2019s Laboratories. \u201cBringing a more affordable generic version to market creates greater patient access for this important drug.\u201d\n<\/p>\n

\nAs previously announced<\/a>, Celgene agreed to provide Dr. Reddy\u2019s with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S. in settlement of all outstanding claims of its litigation. The agreed-upon percentages remain confidential. As part of the settlement, Dr. Reddy\u2019s is also licensed to sell generic lenalidomide capsules in the U.S. without volume limitation beginning on January 31, 2026.\n<\/p>\n

\nDr. Reddy\u2019s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.\n<\/p>\n

\nPlease click here<\/a> to see the full prescribing information, along with boxed warning for Dr. Reddy\u2019s Lenalidomide Capsules.\n<\/p>\n\n\n
\n

\n\u00a0\n<\/p>\n

\nWARNING: EMBRYO-FETAL TOXICITY, HEMATOLOGIC TOXICITY,
\n
and VENOUS and ARTERIAL THROMBOEMBOLISM<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nSee full prescribing information for complete boxed warning.<\/i>\n<\/p>\n

\n\u00a0\n<\/p>\n

\nEMBRYO-FETAL TOXICITY<\/span>\n<\/p>\n